Certain Restricted Stock Units of Vera Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 14-MAR-2024.
March 13, 2024
Share
Certain Restricted Stock Units of Vera Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 14-MAR-2024. These Restricted Stock Units will be under lockup for 45 days starting from 29-JAN-2024 to 14-MAR-2024.
Details:
The directors and executive officers, and certain stockholders affiliated with its directors, referred to herein as lock-up parties, have entered into lock up agreements with the underwriters prior to the commencement of this offering pursuant to which each lock-up party, with limited exceptions, for a period of 60 days, in the case of directors and executive officers, or 45 days, in the case of certain stockholders affiliated with directors, after the date of this prospectus supplement, referred to herein as the restricted period, may not, without the prior written consent of J.P. Morgan Securities LLC, Cowen and Company, LLC and Evercore Group L.L.C., (1) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend or otherwise transfer or dispose of, directly or indirectly, any shares of Class A or Class B common stock, or common stock, or any securities convertible into or exercisable or exchangeable for its common stock
Vera Therapeutics, Inc. is a late-stage biotechnology company. The Company is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Its product candidate, atacicept, is a self-administered fusion protein that blocks both a B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL) which stimulates B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases. The Company is also engaged in developing MAU868, a monoclonal antibody designed to neutralize infection with BK Virus, a polyomavirus that can have devastating consequences in certain settings such as kidney transplants. The Company is conducting a randomized, double-blind, placebo-controlled Phase 3 clinical trial in IgAN, which it refers to as ORIGIN 3, and completing the open label extension of its Phase 2b clinical trial in IgAN, which it refers to as ORIGIN 2b.